MedPath

Assess the Impact of MyTatva Application in Management of Chronic Obstructive Pulmonary Disease.

Phase 4
Conditions
Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified
Registration Number
CTRI/2023/09/057886
Lead Sponsor
Digicare Health Solutions Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Subject will be eligible for inclusion in this study only if all of the

following criteria apply:

1. Male or female patients >40 years of age with confirmed diagnosis of moderate to severe COPD as per GOLD guidelines with no exacerbations within last 12 months.

2. Patient having FEV1 = 40% and = 80% (without using bronchodilator) of the predictable value.

3. Patient is willing and able to provide written informed consent.

4. Patient is willing to comply with all study procedures and available for the duration of the study.

5. Patient with access to a smartphone with internet access.

6. Patient who will be able to use MyTatva App.

Exclusion Criteria

Subject will not be eligible for inclusion in this study if any of the

following criteria apply:

1. Persistent COPD with history of hospitalization in the last 6 months and unstable in the last 2 months.

2. Unable to read, write, or understand English.

3. The patient is not able to participate the exercise training program due to physical, cognitive or safety reasons, as judged by investigator, e.g., lower limb joint surgery within preceding 3 months, unstable cardiac disease, predominant neurological limitations and planned surgical or other interventions disturbing the study intervention.

4. Patient who is pregnant or planning to become pregnant.

5. Concurrent participation in any other interventional clinical trial.

6. Presumed or confirmed COVID-19 diagnosis within 30 days prior to randomization.

7. Co-existing known malignancy.

8. Patient not willing to perform coaching as instructed.

9. Patient with interstitial lung disease.

10. Severe exacerbations in last one month.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of life improvement (St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) questionnaire score), Improvement in functional capacity Six-minute walk test (6MWT), Percentage of patients with adherence to diet, exercise and medication (using questionnaire) <br/ ><br> <br/ ><br>Timepoint: Change from baseline to Week 12 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Improvement in lung function capacity – FEV1, FVC <br/ ><br>Improvement in serum protein <br/ ><br>Improvement in BMI <br/ ><br>Timepoint: Change from baseline to Week 12
© Copyright 2025. All Rights Reserved by MedPath